EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Zilucoplan: A Newly Approved Macrocyclic Peptide for Treatment of Anti-Acetylcholine Receptor Positive Myasthenia Gravis

Lia Costa, Carla Fernandes

Drugs and Drug Candidates · 27.03.2024 · 3 (2) · 311-327

DOI: 10.3390/ddc3020018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 27.03.2024. Verfasst von Lia Costa und 1 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FCT (Foundation for Science and Technology), Group of Marine Natural Products and Medicinal Chemistry–CIIMAR.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zilucoplan is a synthetic macrocyclic peptide approved by the Food and Drug Administration (FDA), in October 2023, for the treatment of generalized myasthenia gravis. It is considered as an orphan drug that causes the inhibition of terminal complement cascade activation with a dual mechanism of action preventing the formation of the membrane attack complex (MAC) and the destruction of the neuromuscular junction. This drug has been demonstrated to be able to treat the generalized myasthenia gravis without significant adverse effects, with good efficacy, safety, and tolerability profile. Zilucoplan is not only innovative and promising in the therapeutics of generalized myasthenia gravis, but it could also be beneficial for the treatment of other diseases as well as a model for synthesis of analogues to improve pharmacological profile.

Förderung

  • FCT (Foundation for Science and Technology)
  • Group of Marine Natural Products and Medicinal Chemistry–CIIMAR

Zitieren

APA

Costa, L., & Fernandes, C. (2024). Zilucoplan: A Newly Approved Macrocyclic Peptide for Treatment of Anti-Acetylcholine Receptor Positive Myasthenia Gravis. Drugs and Drug Candidates, 3(2), 311-327. https://doi.org/10.3390/ddc3020018

Vancouver

Costa L, Fernandes C. Zilucoplan: A Newly Approved Macrocyclic Peptide for Treatment of Anti-Acetylcholine Receptor Positive Myasthenia Gravis. Drugs and Drug Candidates. 2024;3(2):311-327. doi:10.3390/ddc3020018

BibTeX
@article{Costa2024,
  author = {Costa, Lia and Fernandes, Carla},
  title = {Zilucoplan: A Newly Approved Macrocyclic Peptide for Treatment of Anti-Acetylcholine Receptor Positive Myasthenia Gravis},
  journal = {Drugs and Drug Candidates},
  year = {2024},
  volume = {3},
  number = {2},
  pages = {311--327},
  doi = {10.3390/ddc3020018}
}
Kostenlos starten →